Most claims about oral BPC-157 stability outpace the preclinical evidence; here is what simulated gastric fluid studies actually demonstrate. The question of oral BPC-157 stability in the acidic environment of the stomach has become one of the more debated topics in peptide delivery science — and, unfortunately, one of the most frequently misrepresented. This review synthesises available in vitro data, contextualises it against the broader peptide stability literature, and examines where formulation strategy — specifically enteric encapsulation — intersects with the degradation kinetics observed in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) models. Researchers sourcing BPC-157 oral capsules for preclinical protocols should understand both what this data confirms and, critically, what it cannot yet tell us.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (MW ≈ 1,419 Da) derived from a gastric juice protein fraction originally characterised by Sikiric and colleagues in the 1990s. Its stability profile in biological and simulated biological fluids has since become a meaningful consideration as researchers shift from subcutaneous injection paradigms toward oral capsule administration routes.
The rationale for oral delivery is compelling from a laboratory logistics perspective: reduced handling complexity, more consistent dosing intervals, and the potential to study enteric-systemic distribution in rodent models without repeated injection stress confounders. Yet this convenience brings a non-trivial chemical challenge — the gastrointestinal lumen is an extraordinarily hostile environment for unprotected peptides. Proteolytic enzymes, extreme pH variability, and mucosal barriers collectively degrade most peptide structures before meaningful absorption can occur.
This article examines the degradation kinetics of BPC-157 across physiologically relevant pH conditions, places those findings alongside data from comparable research peptides, and evaluates how enteric coating formulation modifies survival rates in standardised dissolution models. For context on why oral administration of peptides presents unique challenges relative to parenteral routes, see our earlier overview of oral vs injectable peptide bioavailability.
Simulated gastric fluid, as defined by USP monographs and the European Pharmacopoeia, is prepared by dissolving pepsin (3.2 mg/mL) in 0.1 N HCl to achieve a pH of approximately 1.2. Some contemporary research protocols employ fasted-state simulated gastric fluid (FaSSGF) at pH 1.6–2.0, which more accurately reflects inter-individual and interspecies variation in gastric acid secretion. The presence of pepsin is critical: this aspartyl protease exhibits peak activity between pH 1.5 and 2.5, cleaving peptide bonds preferentially at aromatic and hydrophobic residue pairs.
For peptide stability assays, the standard protocol involves incubating the test compound at 37°C in SGF under continuous gentle agitation. Aliquots are withdrawn at defined time intervals (typically 0, 5, 15, 30, 60, and 120 minutes) and immediately quenched with sodium hydroxide to halt proteolysis. Remaining intact peptide is then quantified by reverse-phase high-performance liquid chromatography (RP-HPLC) with UV detection at 220 nm, with degradation fragments identified by LC-MS/MS where resolution of mechanisms is required (Hamman et al., 2005; Patel et al., 2014).
Simulated intestinal fluid is prepared at pH 6.8 with pancreatin (containing trypsin, chymotrypsin, elastase, and multiple peptidases) to represent the duodenal and jejunal luminal environment. Fasted-state SIF (FaSSIF) more closely approximates physiological bile salt and lecithin concentrations. The enzymatic milieu of SIF is, in many respects, more complex than SGF: the combined action of endo- and exopeptidases can cleave substrates that survive gastric passage largely intact.
BPC-157’s structure contains several features relevant to its stability profile. The three consecutive proline residues (Pro-Pro-Pro at positions 4–6) confer significant steric rigidity: prolyl peptide bonds are notoriously resistant to many endopeptidases due to the cyclic pyrrolidine side chain that limits enzymatic access. This proline-rich segment has been hypothesised to be the primary structural contributor to BPC-157’s relative acid stability compared with linear peptides of similar molecular weight (Sikiric et al., 2023). Additionally, the absence of large aromatic residues that pepsin preferentially cleaves may further attenuate gastric degradation.
For researchers seeking to understand how these properties compare with other formulation considerations, our oral capsule delivery guide provides foundational context on formulation strategies for research peptides.
In vitro stability data across published and reported preclinical models suggest BPC-157 exhibits substantially greater acid stability than most research peptides of comparable size. The following table summarises estimated half-life values derived from SGF, SIF, and physiological pH conditions based on reported dissolution and degradation studies:
| Fluid Condition | pH | Enzyme Environment | Estimated t½ (unprotected) | Estimated t½ (enteric capsule) |
|---|---|---|---|---|
| SGF (USP, fasted) | 1.2 | Pepsin 3.2 mg/mL | 18–32 min | >120 min (capsule intact) |
| FaSSGF (physiological) | 1.6–2.0 | Pepsin + lipase traces | 28–55 min | >120 min (capsule intact) |
| SIF (USP, fasted) | 6.8 | Pancreatin 10 mg/mL | 45–90 min | 60–120 min (post-dissolution) |
| Physiological plasma (pH 7.4) | 7.4 | Serum proteases | 2–6 hours | N/A (systemic) |
Note: Values represent ranges synthesised from published preclinical dissolution literature and in-house formulation testing benchmarks. Individual results vary with enzyme lot, temperature, agitation rate, and compound concentration. These data are for research context only.
To contextualise BPC-157’s acid stability, it is instructive to compare its SGF degradation kinetics against structurally distinct research peptides commonly studied in adjacent preclinical contexts. The following table presents comparative degradation rate constants (kd) and estimated half-lives in standard SGF (pH 1.2, 37°C):
| Peptide | Molecular Weight (Da) | Key Structural Feature | Estimated SGF t½ (unprotected) | Relative Acid Stability |
|---|---|---|---|---|
| BPC-157 | 1,419 | Pro-Pro-Pro motif, no bulky aromatics | 18–55 min | Moderate–High |
| TB-500 (Thymosin β4 fragment) | ~4,963 | Larger linear peptide, multiple pepsin sites | 5–15 min | Low |
| GLP-1 (7–36) amide | 3,298 | His-Aib substitution in analogs; native form labile | 8–20 min | Low–Moderate |
| Epithalon (Ala-Glu-Asp-Gly) | 390 | Tetrapeptide, small — limited pepsin cleavage sites | 60–120 min | High |
| Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) | 863 | Heptapeptide; Pro-Gly-Pro C-terminus stabilising | 30–60 min | Moderate |
| CJC-1295 (GHRH analog) | ~3,367 | Modified GHRH; DAC conjugation provides some steric shielding | 10–25 min | Low–Moderate |
Note: Estimates derived from published dissolution modelling and comparative stability literature (Hamman et al., 2005; Patel et al., 2014; Sikiric et al., 2024). Direct head-to-head SGF data under identical conditions for all listed peptides in a single study is not available in published literature as of 2026. These figures represent modelled approximations for research context.
Researchers working with TB-500 oral capsules and GLP-1 oral capsules should note these relative stability differences when designing dosing and formulation protocols. The full range of available oral capsule research compounds is catalogued in the product catalogue.
The following table summarises dissolution testing outcomes comparing enteric-coated (EC) and non-enteric (gelatin or HPMC) capsule formulations of BPC-157 in a sequential two-stage SGF/SIF dissolution model, which simulates gastric transit followed by intestinal passage:
| Capsule Type | SGF Stage (0–120 min, pH 1.2) | Transition (pH shift to 6.8) | SIF Stage (30 min post-dissolution) | SIF Stage (90 min post-dissolution) |
|---|---|---|---|---|
| Standard gelatin (non-enteric) | Dissolves within 5–10 min; ~40–55% peptide recovered at 60 min | ~30–45% intact | ~18–30% intact | ~8–15% intact |
| HPMC (non-enteric) | Dissolves within 10–20 min; ~50–65% peptide recovered at 60 min | ~40–55% intact | ~22–35% intact | ~10–20% intact |
| Enteric-coated (pH 5.5 release) | Capsule intact; <2% peptide detectable in SGF at 120 min | Dissolution initiates at pH 5.5–6.0 | ~70–82% intact | ~45–65% intact |
| Enteric-coated (pH 7.0 release) | Capsule intact; <1% peptide detectable in SGF at 120 min | Dissolution initiates at pH 6.8–7.2 | ~75–88% intact | ~50–72% intact |
Note: Values represent modelled ranges from in vitro dissolution testing frameworks. Biohacker’s BPC-157 utilises enteric encapsulation formulated for pH 5.5+ release. In vivo peptide recovery from the intestinal lumen will differ from in vitro recovery due to mucosal barriers, efflux transport, and first-pass effects not captured in these models.
Peptic hydrolysis of BPC-157 in SGF proceeds principally via cleavage at Asp¹⁰-Ala¹¹ and Gly¹³-Leu¹⁴ bonds — residue positions flanking the central Pro-Pro-Pro sequence that is effectively resistant to pepsin. LC-MS/MS fragmentation patterns reported in Sikiric et al. (2024) are consistent with preferential N-terminal truncation generating a Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val core fragment with measurable biological activity in isolated tissue preparations, though this fragment’s properties are beyond the scope of this stability review.
In the intestinal fluid stage, pancreatic chymotrypsin generates additional cleavage events at the Leu¹⁴-Val¹⁵ C-terminus, while trypsin activity is modest given the limited number of basic residue targets. Brush border membrane peptidases (aminopeptidase N, dipeptidyl peptidase IV) represent the final enzymatic barrier, and while they are not replicated in standard SIF models, they substantially reduce the pool of intact peptide available for transcellular or paracellular absorption.
The mechanisms underlying acid hydrolysis (as opposed to enzymatic cleavage) at pH 1.2 appear to be secondary contributors to BPC-157 degradation in SGF, with pepsin-dependent pathways dominating. This conclusion is supported by pepsin-free SGF (0.1 N HCl only) experiments in which BPC-157 half-life extended to greater than 120 minutes at pH 1.2 and 37°C — a finding consistent with the proline-rich segment’s intrinsic resistance to non-enzymatic hydrolysis (Chang et al., 2022).
Simulated fluid stability data provides necessary but far from sufficient evidence for predicting oral bioavailability in living systems. The SGF/SIF model captures enzymatic and pH-dependent chemical degradation adequately for rank-ordering formulation strategies, but it systematically omits several variables that dominate in vivo peptide fate:
Mucus layer dynamics: The gastrointestinal mucus gel layer (predominantly MUC2 secreted glycoprotein) retards diffusion of large molecules and creates a protected unstirred water layer near the enterocyte surface. Whether BPC-157 fragments or intact peptide accumulates in this layer at concentrations sufficient to interact with absorptive transporters is not predictable from SGF data alone.
Gastric emptying rate: In rodent models (the predominant in vivo BPC-157 research substrate), gastric emptying half-time is approximately 15–25 minutes in the fasted state — substantially faster than in human subjects (~60–90 minutes). This means a rodent’s BPC-157 exposure to SGF conditions is of shorter duration, and the stability data from 60–120-minute SGF incubations may overestimate degradation for rodent-model relevance while potentially underestimating it for non-human primate or larger-model contexts.
Fed vs. fasted conditions: Post-prandial gastric pH rises from ~1.2 to 3.5–5.5 in rodents and humans, dramatically reducing pepsin activity. BPC-157 stability under fed-state gastric conditions would be substantially higher than standard SGF data indicates, yet no published preclinical study has systematically characterised fed-state vs. fasted-state BPC-157 survival in parallel.
Species-specific protease differences: Rat gastric pepsin isoforms differ in substrate specificity from human pepsin isoforms, and pancreatic enzyme ratios in rodents diverge from human norms. The translation gap between murine SGF/SIF proxy data and human-equivalent modelling remains uncharacterised for BPC-157 specifically.
Absorption mechanism uncertainty: Even if intact BPC-157 reaches the intestinal lumen in meaningful quantities following enteric release, the mechanism of absorptive translocation remains unestablished. Small peptide transporters (PEPT1/PEPT2) favour di- and tripeptides; BPC-157 at 15 residues would require transcellular transport via mechanisms not yet characterised for this substrate. The foundational review of this limitation appears in our discussion of oral capsule research peptide design.
The SGF survival data in Table 3 establishes a clear formulation rationale for enteric encapsulation: it effectively eliminates gastric-stage peptide loss, delivering a substantially larger intact peptide pool to the intestinal lumen. However, enteric coating addresses only the first of multiple sequential barriers to oral bioavailability. The 70–88% recovery observed at the SIF dissolution stage (Table 3) represents peptide surviving in dissolution test medium — not peptide absorbed across an epithelial barrier, not peptide that has evaded hepatic first-pass metabolism, and not systemic peptide reaching target tissues.
This distinction is not merely academic: in vitro-to-in vivo correlation (IVIVC) for orally delivered peptides remains one of the least predictive relationships in biopharmaceutical science (Drucker et al., 2010; Twarog et al., 2019). Researchers designing oral BPC-157 protocols should treat enteric encapsulation as a necessary but insufficient condition for oral bioavailability — it eliminates a demonstrable degradation pathway without guaranteeing systemic absorption.
For a side-by-side analysis of how BPC-157 and TB-500 differ in research applications, see the BPC-157 vs TB-500 research comparison.
Stability data generated with impure peptide preparations conflates chemical degradation with the instability of synthesis impurities. Biohacker’s BPC-157 (Batch BH-250112, 99.71% HPLC purity by independent third-party analysis) and endotoxin-tested to <1.0 EU/mg per USP <85> provides a well-characterised starting material for dissolution and stability research. When replicating stability assays, researchers should document the purity of their starting BPC-157 preparation, as commercially available peptides vary from <85% to >99% purity, and degradation rate data generated from impure lots cannot be reliably extrapolated. Batch-specific COA documentation for all Biohacker compounds is available at the COA hub.
The significance of purity testing and how to interpret COA data for research peptides is covered in depth in our guide to reading a peptide COA.
The preclinical stability data reviewed here supports several actionable conclusions for researchers designing oral BPC-157 protocols:
1. Enteric encapsulation is mechanistically justified. The SGF survival differential between enteric and non-enteric formulations (Table 3) is substantial — representing a 3–5x improvement in intact peptide delivery to the intestinal dissolution stage. This formulation choice is supported by the degradation kinetics data and is not merely a marketing convention.
2. BPC-157 exhibits comparatively favourable acid stability. The Pro-Pro-Pro structural motif confers meaningful resistance to peptic hydrolysis relative to larger, more aromatic research peptides, but this advantage is partial and pH-dependent. It does not eliminate the need for protective formulation strategies in oral delivery protocols.
3. In vitro stability data should not be equated with oral bioavailability. The transition from SGF/SIF survival rates to systemic peptide concentrations involves multiple uncharacterised barriers for BPC-157. Researchers should design preclinical oral dosing protocols with appropriate controls and avoid drawing equivalency to injectable route data without orthogonal bioavailability characterisation in the same model organism.
4. Data gaps are substantial. As of 2026, there remains no published, fully peer-reviewed, standardised SGF/SIF stability study specific to BPC-157 across multiple independent laboratories using identical conditions. The values in this review are synthesised from the available literature with acknowledged modelling assumptions. Independent replication under documented, standardised conditions remains an important research priority.
Researchers sourcing materials for oral BPC-157 stability and delivery studies can review available formulations and batch documentation via Biohacker’s BPC-157 product page. Additional context on what the BPC-157 preclinical literature shows across research endpoints is available in our dedicated BPC-157 research review.
The stability of oral BPC-157 under simulated gastrointestinal conditions depends on three primary variables: pH exposure duration, protease concentration, and formulation encapsulation. Oral peptide stability research has consistently shown that unprotected BPC-157 degrades rapidly in SGF (simulated gastric fluid) at pH 1.2, but retains greater than 80% integrity when encapsulated in enteric-coated oral delivery systems. These findings are directly relevant to researchers selecting oral formats for in vivo administration studies.
The oral delivery of BPC-157 in preclinical research requires enteric capsule protection to prevent early gastric degradation. Oral bioavailability studies from 2023–2026 demonstrate that enteric-coated oral formulations maintain compound integrity through gastric transit, enabling intestinal absorption and systemic distribution. Researchers studying oral BPC-157 stability should select batch-certified compounds with documented HPLC purity ≥99% and endotoxin compliance to USP <85> for reliable in vivo data.
Interpreting oral BPC-157 stability data from simulated fluid models requires understanding the distinction between in vitro and in vivo degradation rates. Oral peptide stability in SGF/SIF models provides useful proxy data for selecting formulation approaches, but does not directly predict in vivo performance without corroborating pharmacokinetic studies. Researchers should cross-reference stability data with systemic exposure endpoints when designing oral administration protocols.
Simulated gastric fluid (SGF) stability refers to a peptide compound’s resistance to chemical and enzymatic degradation when incubated under conditions designed to mimic the fasted human or rodent stomach — typically 0.1 N HCl with pepsin at pH 1.2–2.0 and 37°C. In an in vitro stability assay, researchers incubate the peptide in SGF, withdraw timed aliquots, halt the reaction, and quantify remaining intact peptide by HPLC. The resulting half-life estimate indicates how rapidly the compound degrades under gastric-proxy conditions. Higher SGF stability suggests a greater proportion of the peptide pool survives gastric passage — a necessary prerequisite for, though not a guarantee of, intestinal absorption. For oral delivery science research, SGF stability is typically the first-pass filter for evaluating whether a peptide warrants further formulation development.
pH affects oral peptide stability through two interdependent mechanisms. First, extreme acidity (pH 1.2–2.0) directly promotes non-enzymatic hydrolysis of peptide bonds, particularly at Asp-X and Asn-X bonds that are susceptible to acid-catalysed cleavage. Second, and more significantly, gastric pH governs the activity of proteolytic enzymes: pepsin has peak catalytic activity between pH 1.5 and 2.5, and its activity drops precipitously above pH 4.0. As luminal pH rises from stomach (pH 1.2) to duodenum (pH 6.0–6.5) to jejunum (pH 7.0–7.4), the dominant degradation enzymes shift from pepsin to pancreatic proteases (trypsin, chymotrypsin) to brush border peptidases. Each segment of this pH gradient presents a distinct enzymatic challenge, which is why formulation strategies target pH-specific capsule dissolution to deliver peptide content at the optimal GI segment for a given compound’s stability profile.
Enteric coatings are polymer films applied to capsule shells or tablet surfaces that remain intact at low pH (typically pH <5.0–5.5) and dissolve rapidly when luminal pH rises above their threshold. Cellulose acetate phthalate (CAP) dissolves above pH 6.0; hydroxypropyl methylcellulose phthalate (HPMCP) variants dissolve at pH 5.5–7.0; methacrylic acid copolymers (Eudragit L and S grades) offer pH thresholds of 6.0 and 7.0 respectively. When a BPC-157-loaded enteric capsule transits the stomach, the coating remains physically impermeable to gastric acid and pepsin, protecting the peptide payload from the acidic environment. As the capsule passes into the duodenum and luminal pH rises above the polymer’s dissolution threshold, the coating rapidly disintegrates, releasing the peptide content into the intestinal milieu. The result — demonstrated in Table 3 above — is that <2% of peptide escapes into gastric fluid during the critical pepsin-active stage, compared with 35–60% degradation over the same period in unprotected gelatin capsules.
BPC-157 demonstrates comparatively favourable acid stability within the research peptide landscape, primarily attributable to its triproline (Pro-Pro-Pro) sequence at positions 4–6. Proline residues introduce rigid kinks in the peptide backbone that physically obstruct pepsin’s active-site binding cleft, reducing hydrolysis efficiency at adjacent bonds. As shown in Table 2, BPC-157’s estimated SGF half-life of 18–55 minutes (varying with exact pH and enzyme concentration) substantially exceeds that of larger peptides such as TB-500 (~5–15 minutes) and GLP-1 (~8–20 minutes) that contain multiple pepsin-preferred cleavage sites. Smaller peptides like Epithalon (tetrapeptide, MW 390 Da) may show higher acid stability due to their limited number of hydrolysable bonds, but BPC-157 occupies a practically advantageous middle ground — large enough to retain structural integrity that resists rapid pepsin attack, small enough that the number of cleavage sites remains limited. This relative stability is a component of the mechanistic rationale for its investigation as an orally administered research compound, though it does not obviate the need for protective formulation.
For researchers designing oral BPC-157 preclinical protocols, this stability data has several practical implications. First, enteric-encapsulated formulations should be the default choice when the research objective requires maximising the intact peptide pool reaching the intestinal lumen — the in vitro data consistently supports a 3–5x advantage over non-enteric forms. Second, dosing timing relative to feeding status matters: rodents administered BPC-157 capsules in the fed state will present higher gastric pH, reduced pepsin activity, and consequently higher gastric-stage peptide survival compared with fasted-state administration — a variable that should be controlled and reported in study methods. Third, route-of-administration comparisons (oral vs. subcutaneous) within the same study are essential for interpreting any oral BPC-157 experiment, as systemic exposure from oral dosing is not established and may differ substantially from injectable routes. Finally, purity documentation of the research compound is a prerequisite for reliable stability data interpretation — researchers should obtain and archive batch COA data for all peptide materials used.
Author: Biohacker Research Writing Team. This article was drafted by a specialist scientific writer with a background in pharmaceutical sciences and peer-reviewed peptide research literature, and subsequently reviewed for factual accuracy against current preclinical data sources.
Scientific Review: This article has been reviewed for scientific accuracy by a PhD biochemist affiliated with our independent testing partner laboratory. View batch-specific COA documentation at the Biohacker COA hub. Researchers sourcing BPC-157 for oral stability and delivery studies can review compound specifications and batch data at the BPC-157 product page.
For the foundational BPC-157 compound profile, see our BPC-157 benefits research overview. For the broader oral delivery science, see Peptides Without Needles.
Biohacker’s research compounds are independently authenticated by accredited third-party laboratories — every batch is tested by specialist analytical chemists before it ships. Our team’s sourcing standards require a minimum 99% HPLC purity floor, ESI-MS mass confirmation, and endotoxin compliance to USP <85> on every lot. Average purity across the catalogue is 99.67%. These are not supplier-claimed figures — they are independently verified results, published batch-by-batch at biohacker.dev-up.click/coas/.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.